10x Genomics, Inc. (TXG) · Aug 6, 2026 · Company update

Revenue beat modestly and guidance rose, but instrument demand remains weak

Revenue beat modestly and guidance rose, but instrument demand remains weak

The quarter came in slightly ahead of published expectations. Revenue was $151.0 million versus a published consensus near $148 million, while reported EPS of $(0.14) compared with an estimate near $(0.25), making the headline result a modest beat rather than a major upside surprise.

$ millions, except EPSQ2 2026Q2 2025Market reference
Total revenue151.0172.9~148.0 consensus
Products and services revenue149.1145.2—
License and royalty revenue1.927.8—
Gross margin74%72%—
Net income (loss)(17.9)34.5—
Diluted EPS(0.14)0.28~(0.25) consensus
Full-year revenue guidance610–630—Prior: 600–625

The underlying revenue mix was better than the headline decline suggests. Total revenue fell 13% year over year because prior-year patent-settlement revenue was unusually large; excluding settlements, revenue rose 3% (Financial Highlights). Consumables increased 7% to $130.8 million, led by 16% growth in spatial consumables, while services rose 26% (Revenue by Product Type). That recurring consumables growth is the healthier part of the quarter.

Instrument demand was the clear weak spot. Instrument revenue fell 47% to $7.7 million, with Single Cell instruments down 46% and Spatial instruments down 48% (Revenue by Product Type). Management attributed the positive outlook to early Atera order flow, but the filing provides no unit, backlog, or revenue detail to establish that the new platform has yet offset the current purchasing slowdown.

The guidance increase is real but narrow. Full-year revenue guidance moved from $600–625 million to $610–630 million, raising the midpoint by only about 1.2% (Outlook). The company now expects 2%–5% growth excluding settlement revenue, so the raise improves the near-term setup but does not represent a major reset in growth expectations.

Profitability improved operationally, though reported losses widened. Gross margin rose to 74% from 72%, helped by lower manufacturing costs, $2.6 million of tariff refunds, and fewer inventory write-downs (Financial Highlights). Reported operating expenses rose 39%, but excluding settlement effects they were approximately flat; the larger loss mainly reflects the absence of the prior year’s $40.7 million settlement gain (Income Statement). Cash and marketable securities totaled about $552 million at June 30, providing substantial financial flexibility (Balance Sheet).

Net read: mildly positive versus expectations, with an important qualification. The revenue and EPS beats, higher full-year guidance, and recurring consumables growth outweigh the weak instrument quarter. However, the small guidance lift and lack of quantified Atera contribution keep this from being a broad upside re-rating of the business.

Original filing on SEC EDGAR

More 10x Genomics, Inc. news

Revenue beat modestly and guidance rose, but instrument demand remains weak | TXG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.